SCHEMBL850437

SCHEMBL850437

O=C(Nc1ccc(Br)c(C(F)(F)F)c1)C1CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 5/20 0.62
▸ KMT2A Q03164 4/20 0.62
▸ LMNA P02545 4/20 0.62
▸ MEN1 O00255 3/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ ALOX12 P18054 2/20 0.62
▸ HPGD P15428 1/20 0.62
▸ ALOX15 P16050 1/20 0.62
▸ MAPT P10636 6/20 0.58
▸ NPSR1 Q6W5P4 3/20 0.58
▸ XBP1 P17861 1/20 0.58
▸ EPHX1 P07099 2/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ TMPRSS4 Q9NRS4 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.48
▸ TAS2R14 Q9NYV8 1/20 0.48
▸ NAMPT P43490 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16358071 0.89 KMT2A (0.59) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL17236532 0.80 KMT2A (0.68) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL31421815 0.79 ULK1 (0.52) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL30977691 0.78 EPHX1 (0.74) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL1431941 0.78 EPHX1 (0.74) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL8527587 0.78 MAPT (0.64) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL2705806 0.78 MAPT (0.64) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL25273344 0.77 KMT2A (0.63) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL31642809 0.77 MAPT (0.74) HTTKMT2ALMNAMEN1SMN1; SMN2
SCHEMBL11435538 0.77 EGFR (0.51) KMT2ALMNAMEN1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 — — US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 HTT 1584/4885KMT2A 3163/4885LMNA 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback